Thrivent Financial for Lutherans
SAGE icon

Thrivent Financial for Lutherans’s Sage Therapeutics SAGE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-74,625
Closed -$405K – 2514
2024
Q4 		$405K Buy
74,625
+38,876
+109% +$238K ﹤0.01% 2330
2024
Q3 		$258K Hold
35,749
– – ﹤0.01% 2425
2024
Q2 		$389K Buy
+35,749
New +$458K ﹤0.01% 2312
2023
Q2 		– Sell
-30,567
Closed -$1.28M – 2528
2023
Q1 		$1.28M Hold
30,567
– – ﹤0.01% 1625
2022
Q4 		$1.17M Buy
30,567
+24,440
+399% +$933K ﹤0.01% 1628
2022
Q3 		$240K Buy
+6,127
New +$237K ﹤0.01% 2299
2022
Q2 		– Sell
-6,127
Closed -$203K – 2502
2022
Q1 		$203K Sell
6,127
-41,012
-87% -$1.54M ﹤0.01% 2447
2021
Q4 		$2M Buy
+47,139
New +$1.97M ﹤0.01% 1401
2021
Q2 		– Sell
-19,883
Closed -$1.49M – 2516
2021
Q1 		$1.49M Sell
19,883
-17,622
-47% -$1.44M ﹤0.01% 1600
2020
Q4 		$3.24M Sell
37,505
-10,721
-22% -$790K 0.01% 1048
2020
Q3 		$2.95M Sell
48,226
-928
-2% -$47K 0.01% 975
2020
Q2 		$2.04M Buy
49,154
+131
+0.3% +$4.75K 0.01% 1045
2020
Q1 		$1.41M Sell
49,023
-18,556
-27% -$1.07M 0.01% 1116
2019
Q4 		$4.88M Buy
67,579
+7,265
+12% +$894K 0.01% 741
2019
Q3 		$8.46M Buy
60,314
+1,542
+3% +$258K 0.03% 552
2019
Q2 		$10.8M Buy
58,772
+333
+0.6% +$56.8K 0.03% 491
2019
Q1 		$9.29M Buy
58,439
+576
+1% +$83.4K 0.03% 497
2018
Q4 		$5.54M Buy
57,863
+38,745
+203% +$4.43M 0.02% 589
2018
Q3 		$2.7M Sell
19,118
-2,319
-11% -$358K 0.01% 791
2018
Q2 		$3.35M Buy
21,437
+115
+0.5% +$18.1K 0.01% 740
2018
Q1 		$3.43M Buy
21,322
+272
+1% +$46.2K 0.01% 734
2017
Q4 		$3.47M Buy
+21,050
New +$2.04M 0.01% 739

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Thrivent Financial for Lutherans's SAGE Position: Q1 2025 in Review

Thrivent Financial for Lutherans sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 74,625 shares — an estimated $405K sold.

Thrivent Financial for Lutherans first reported a position in SAGE in Q4 2017 and held it in 22 quarters. The position peaked at $10.8M in Q2 2019. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Thrivent Financial for Lutherans reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 74,625 Sage Therapeutics shares in Q1 2025, an estimated $405K.
  • Thrivent Financial for Lutherans first reported a position in Sage Therapeutics in Q4 2017 and held it in 22 quarters.
  • Thrivent Financial for Lutherans's Sage Therapeutics position peaked at $10.8M in Q2 2019.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2025, filed 13 May 2025.